Bicycle Therapeutics Ltd (BCYC) - Total Liabilities
Based on the latest financial reports, Bicycle Therapeutics Ltd (BCYC) has total liabilities worth $145.47 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check BCYC asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Bicycle Therapeutics Ltd - Total Liabilities Trend (2016–2024)
This chart illustrates how Bicycle Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see BCYC total assets.
Bicycle Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of Bicycle Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Loncor Resources Inc
TO:LN
|
Canada | CA$1.78 Million |
|
inTest Corporation
NYSE MKT:INTT
|
USA | $47.69 Million |
|
Spurcorp
JSE:SUR
|
South Africa | ZAC623.00 Million |
|
NovaBridge Biosciences
NASDAQ:NBP
|
USA | $131.67 Million |
|
Huxen Corp
TW:2433
|
Taiwan | NT$3.22 Billion |
|
Yatra Online Limited
NSE:YATRA
|
India | Rs5.06 Billion |
|
Unison Co. Ltd
KQ:018000
|
Korea | ₩169.84 Billion |
|
Tumosan Motor ve Traktor Sanayi AS
IS:TMSN
|
Turkey | TL12.82 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Bicycle Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Bicycle Therapeutics Ltd (BCYC) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bicycle Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bicycle Therapeutics Ltd (2016–2024)
The table below shows the annual total liabilities of Bicycle Therapeutics Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $163.81 Million | -27.01% |
| 2023-12-31 | $224.41 Million | +60.49% |
| 2022-12-31 | $139.83 Million | +4.71% |
| 2021-12-31 | $133.54 Million | +103.28% |
| 2020-12-31 | $65.69 Million | +286.51% |
| 2019-12-31 | $17.00 Million | -88.78% |
| 2018-12-31 | $151.45 Million | +24.98% |
| 2017-12-31 | $121.19 Million | +3079.87% |
| 2016-12-31 | $3.81 Million | -- |
About Bicycle Therapeutics Ltd
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT552… Read more